The skyrocketing demand for retatrutide, an experimental weight-loss medication, has spawned a lucrative underground industry of counterfeit drugs, raising alarms among medical professionals and regulators worldwide. While the drug remains in clinical trials, determined consumers are turning to the black market, exposing themselves to unverified substances that may cause severe adverse effects.
Lisa King, one such user, claims to have started taking a fake version of retatrutide in July. She reports losing up to 3kg (6lb) per week while maintaining a healthy diet and exercise routine. King also believes the substance has helped manage symptoms of polyendocrine metabolic ovarian syndrome (PMOS), noting reduced sugar cravings, regulated periods, and increased energy levels. “I’m not sure if it’s due to reta, but my sugar cravings have gone down,” she said. “If I start to experience any negative side effects I’ll just come straight off it.”
However, not all users report positive outcomes. Others have experienced brain fog, nausea, diarrhea, loss of libido, and an inability to feel happiness or joy. Doctors are increasingly concerned about the side effects linked to these illicit products. Dr. Sahira Dar, a GP and chair of the British Islamic Medical Association, urges healthcare providers to ask patients about black market use without judgment to encourage disclosure.
Eli Lilly, the pharmaceutical giant behind retatrutide’s development, has spent nearly a decade working on the drug and is now aggressively combating illegal sales. The company has reported over 14,000 websites, advertisements, and social media posts promoting the unapproved medication. A spokesperson told the BBC: “Any retatrutide available online is unapproved, unverified and simply not worth the risk.”
UK regulators have also stepped up enforcement. The Medicines and Healthcare products Regulatory Agency (MHRA) has conducted raids and seized products claiming to contain retatrutide, working to disrupt illegal importation and distribution channels.
Despite the crackdown, sales persist. Professor O’Shea emphasized the importance of highlighting the dangers of black market drugs while cautioning against dismissing the entire class of GLP-1 medications. “GLP-1s are a major advance in managing obesity,” he said, praising their impact on understanding how the brain regulates cravings and appetite.
For legitimate patients, availability remains distant. Eli Lilly plans to submit its application for US FDA approval early next year, with a legal release in the US not expected until at least the end of 2027. In the UK, if the MHRA grants approval, the drug could reach the market by 2028.
Leave a Reply